express scripts glp 1 coverage does cover GLP-1 drug use driving up health care costs 2026 with Express Scripts – Express Scripts expands Patient Assurance

Purificacin: Tomar 1 mL de la solucin a purificar y pasarla por una columna de extraccin en fase slida catinica previamente activada, a una velocidad de 1 gota/segundo

Why this matters: injectable GLP-1s like semaglutide and tirzepatide achieve 15 to 20% weight reductions, but injections, cost, and adherence limit real-world use (Santulli review, Journal of Diabetes & Metabolic Disorders, 2025)

The proposed mechanism suggests that caffeine and other coffee compounds absorbed through the colonic mucosa might stimulate the liver's production of glutathione S-transferase, an enzyme involved in detoxification pathways

GLP-1 drug penetration below 4% of eligible patients Top GLP-1 market: United States with 62.8% of global GLP-1 weight loss drug revenue Cardiovascular approval catalyst: Wegovy approved for MACE risk reduction following SELECT trial demonstrating 20% reduction in major adverse cardiovascular events Fastest-growing indication: Obstructive sleep apnea at 41.2% CAGR following Zepbound FDA approval November 2025 Market Overview: Why GLP-1 Weight Loss Drug Market Growth Is Accelerating The GLP-1 Weight Loss Drug Market is at an unprecedented commercial inflection point defined by three simultaneous demand accelerators

Preclinical studies have demonstrated that GLP-1 receptors are expressed in various ocular tissues, including the retina, and may play roles in neuroprotection, inflammation modulation, and vascular regulation